Cargando…
CircRNAs in anticancer drug resistance: recent advances and future potential
CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Nu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429705/ https://www.ncbi.nlm.nih.gov/pubmed/32799866 http://dx.doi.org/10.1186/s12943-020-01240-3 |
_version_ | 1783571301315641344 |
---|---|
author | Xu, Tianwei Wang, Mengwei Jiang, Lihua Ma, Li Wan, Li Chen, Qinnan Wei, Chenchen Wang, Zhaoxia |
author_facet | Xu, Tianwei Wang, Mengwei Jiang, Lihua Ma, Li Wan, Li Chen, Qinnan Wei, Chenchen Wang, Zhaoxia |
author_sort | Xu, Tianwei |
collection | PubMed |
description | CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Numerous studies have indicated that circRNAs serve a crucial purpose in cancer biology. CircRNAs regulate tumor behavioral phenotypes such as proliferation and migration through various molecular mechanisms, such as miRNA sponging, transcriptional regulation, and protein interaction. Recently, several reports have demonstrated that they are also deeply involved in resistance to anticancer drugs, from traditional chemotherapeutic drugs to targeted and immunotherapeutic drugs. This review is the first to summarize the latest research on circRNAs in anticancer drug resistance based on drug classification and to discuss their potential clinical applications. |
format | Online Article Text |
id | pubmed-7429705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74297052020-08-18 CircRNAs in anticancer drug resistance: recent advances and future potential Xu, Tianwei Wang, Mengwei Jiang, Lihua Ma, Li Wan, Li Chen, Qinnan Wei, Chenchen Wang, Zhaoxia Mol Cancer Review CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Numerous studies have indicated that circRNAs serve a crucial purpose in cancer biology. CircRNAs regulate tumor behavioral phenotypes such as proliferation and migration through various molecular mechanisms, such as miRNA sponging, transcriptional regulation, and protein interaction. Recently, several reports have demonstrated that they are also deeply involved in resistance to anticancer drugs, from traditional chemotherapeutic drugs to targeted and immunotherapeutic drugs. This review is the first to summarize the latest research on circRNAs in anticancer drug resistance based on drug classification and to discuss their potential clinical applications. BioMed Central 2020-08-17 /pmc/articles/PMC7429705/ /pubmed/32799866 http://dx.doi.org/10.1186/s12943-020-01240-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Xu, Tianwei Wang, Mengwei Jiang, Lihua Ma, Li Wan, Li Chen, Qinnan Wei, Chenchen Wang, Zhaoxia CircRNAs in anticancer drug resistance: recent advances and future potential |
title | CircRNAs in anticancer drug resistance: recent advances and future potential |
title_full | CircRNAs in anticancer drug resistance: recent advances and future potential |
title_fullStr | CircRNAs in anticancer drug resistance: recent advances and future potential |
title_full_unstemmed | CircRNAs in anticancer drug resistance: recent advances and future potential |
title_short | CircRNAs in anticancer drug resistance: recent advances and future potential |
title_sort | circrnas in anticancer drug resistance: recent advances and future potential |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429705/ https://www.ncbi.nlm.nih.gov/pubmed/32799866 http://dx.doi.org/10.1186/s12943-020-01240-3 |
work_keys_str_mv | AT xutianwei circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT wangmengwei circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT jianglihua circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT mali circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT wanli circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT chenqinnan circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT weichenchen circrnasinanticancerdrugresistancerecentadvancesandfuturepotential AT wangzhaoxia circrnasinanticancerdrugresistancerecentadvancesandfuturepotential |